Amgen, Astra Strike $50M Inflammatory Drug Pact - Apr. 3, 2012

Having trouble viewing this email? View in Browser.

Monday, April 02, 2012  |   |   |   |  Challenging Current Paradigms in Early Drug Development Please Join Aptuit at their Medicines Research Centre in Verona Italy Drug Discovery and Development is an expensive and high-risk business that can take 10 years from inception to the commercialization of a new drug. Often associated with high attrition rates, it is driven by medical need, disease prevalence and likelihood of success. Drug Development has traditionally been a long and extensive process designed for a staged assessment of the safety, efficacy and manufacture of a drug candidate. On May 16, 2012, Aptuit will welcome nine distinguished representatives from academia and industry to speak at this FREE symposium where they will cover and discuss aspects and strategies to reduce risk, costs and timelines from Candidate Selection to Phase II Clinical Trials. For a full description of this event, and to register, please go to: www.aptuit.com/verona/paradigms/introduction.aspx.   •  Amgen (AMGN), AstraZeneca PLC (AZN) Strike $50 Million Inflammatory Drug Pact More... •  Stemline Therapeutics, Inc. Files for $50 Million US IPO More... •  Adimab LLC. Raises $13.8 Million Series F Financing, Gets New Digs to Accomodate Growth More... •  UCB, Inc. (UCBJF.PK)'s Neupro® Approved by FDA for Parkinson's Disease and Restless Legs Syndrome More... •  GlaxoSmithKline (GSK) to File GLP-1 Diabetes Drug Albiglutide as Data Impresses More... •  Bayer AG (BAY.F) Gastrointestinal Cancer Drug Meets Phase 3 Trial Goal More... •  Astellas Pharma Inc. (YPH.BE) Overactive Bladder Drug Raises Blood Pressure Dangers, FDA Says More... •  Pfizer Inc. (PFE) Execs to Stand Trial for Cover-up of Drug Trial Results More... More Top News Biomarker Services for Early and Sensitive Detection of Kidney Damage Unexpected drug-induced renal toxicity is one of the leading causes of failure in drug development programs. Researchers have been limited to the use of biomarkers that lack the sensitivity necessary to identify damage before it becomes permanent. In cooperation with Novartis, we have developed renal toxicity biomarkers in order to provide comprehensive, sensitive and quantitative rat and human kidney panels. Please click here for more information. •  Why Stress Might Make You Sick, Carnegie Mellon University Study More... •  Exploring the Antidepressant Effects of Testosterone, Florida State University Study More... •  Genome Sequencing Isn't Predictive of Most Diseases, Johns Hopkins University Study More... •  Estrogen Is Responsible for Slow Wound Healing in Women, University of California, Berkeley (CAL) Study More... •  Ovastacin Cuts Off Sperm Binding, Rockefeller University Study More... •  Caloric Moderation Can Reverse Link Between Low Birth Weight and Obesity, University of California, Los Angeles (UCLA) Study More... •  New Research Could Stop Tumor Cells from Spreading, University of Gothenburg Study More... •  Osteoporosis Drugs May Lead to Eye Trouble, University of British Columbia Study More...   More Featured News SafeBridge Consultants, Inc. announces two Potent Compound Safety Training offerings (may be taken separately or consecutively) The SafeBridge original Potent Compound Safety "Boot Camp"® (Boot Camp I) is a comprehensive two-day course in pharmaceutical potent compound safety focused on training EH&S and related professionals in critical technical concepts and proactive safety programs in pharmaceutical industrial hygiene, occupational and environmental toxicology, analytical chemistry, and risk communication. The SafeBridge Advanced Concepts to Support Drug Development of Potent Compounds from R&D through Manufacturing (Boot Camp II) is a one-day advanced course focused on case studies and problem-solving to address potent compound safety issues in discovery, development, contract manufacturing and commercialization. COURSE SEATING IS LIMITED AND USUALLY SELLS OUT! San Diego, CA Boot Camp I May 15-16, 2012 Boot Camp II May 17, 2012 Contact: Susan Custer: susan.custer@safebridge.com, or 650-961-4820 x 231 or www.safebridge.com. Drug Delivery Partnership Strategies • Learn from interviews with senior drug delivery partnering executives. • Develop effective partnering strategies based on case studies and analysis of market data. • Unlock therapeutic value of new biopharmaceutical developments by strategic collaborations for innovative drug delivery technologies. Click Here for More Information. Building Novel Applications with Pipeline Pilot to Drive Next Generation Sequencing This case study shows how scientists are streamlining the process of analyses of DNA sequence information. Enabled by new DNA sequencing technologies, many more scientists and informaticians are interrogating larger and more complex data set. Request Now! • Biotech Bay (San Francisco, California) Gallus Biopharmaceuticals, LLC Director, Business Development Establish and grow customer relationships to understand the requirements and champion their needs within Gallus BioPharmaceuticals. Research, identify, investigate and develop new business opportunities (Cell Culture) utilizing a variety of resources within the industry. Capture new business opportunities consistent with established Contract Manufacturing Services goals. • Pharm Country (Wayne, Pennsylvania) Octagon Research Solutions, Inc. Recruiting Senior Associate Reporting directly to the Recruitment Manager within our Human Resources Department, the Senior Associate's primary responsibilities will include the following: The Senior Associate takes the lead in recruitment administration, as well as proactively recruiting for entry to mid-level positions. Source and search for qualified candidates according hiring manager requirements. • BioMidwest (Chicago, Illinois) Takeda Pharmaceuticals Manager / Associate Director, Regulatory Strategy Plans/manage/executes all regulatory activities of all levels of complexity for project of responsibility in development and/or supports regulatory activities for assigned marketed product of responsibility. • Biotech Beach (La Jolla, California) Pfizer, Inc Enzymologist/Biochemist, Integrative Biology and Biochemistry Will make important contributions to our molecular and biochemical understanding of oncogenic signaling pathways through the development of robust, automated enzyme assays and selectivity screens to drive the SAR of our oncology projects. • Genetown (Cambridge, Massachusetts) Novartis Institutes for BioMedical Research, Inc. Computational Biologist Will be working in a dynamic, agile 'dry-lab' research environment committed to the discovery of novel drug targets. You will be providing critical support to colleagues by working closely with other investigators to develop mechanistic hypotheses addressing unmet medical needs. Get Noticed! Add your resume to the BioSpace Career Center! See more than 5,000 job postings in the BioSpace Career Center! Biotech Beach Career Fair Job seekers can spend a day with HR representatives and Hiring Managers from top biotech, pharma, medical device and diagnostics companies in the Southern California area. Candidates with a 4-year degree in the life sciences and a minimum of 2-years of industry related experience are invited to attend. (Equivalent work experience may be considered in lieu of a four-year college degree. PhD and Postdoc candidates welcome.) Exhibiting companies are recruiting for positions in areas such as: QA/QC, clinical research, engineering, manufacturing, biostatistics, clinical data management, chemistry, regulatory affairs, and research. Job seekers may register here. • Biotech Beach Career Fair, La Jolla, CA April 17, 2012 • BioCapital Career Fair, Bethesda, MD April 25, 2012 • Pharm Country Career Fair, King Of Prussia, PA May 1, 2012 • BioNC Career Fair, Durham, NC May 2, 2012 • Biotech Bay Career Fair, Burlingame, CA May 29, 2012 More information about BioSpace's Career Fairs BioSpace White Paper Biotech Career Fairs For Job Seekers 101: Control Your Experience By June Salvati, BioSpace Director of Events and Corporate Services Celera Corporation 1401 Harbor Bay Parkway Alameda, California 94502 U.S.A Phone: 510-749-4200 Celera Corporation, acquired by Quest Diagnostics in May 2011, is a healthcare business that uses knowledge of human variability to provide new tests and services to personalize disease management. Our Products business develops and manufactures molecular diagnostic products that are used by hospitals and other clinical laboratories to detect, characterize, monitor and select treatment for disease. More Company Profiles FREE Subscription to PharmaVOICE PharmaVOICE delivers the views, opinions, and insights of executives who are shaping the direction of the dynamic life-sciences industry. Post Your: News | Jobs | Company Profile | Event | Advertising / Sponsorship BioSpace Inc. 6465 South Greenwood Plaza, Suite 400 Centennial, Colorado 80111 U.S.A. Phone: 877-277-7585 Fax: 800-595-2929 BioSpace Inc. 90 New Montgomery Street, Suite 414 San Francisco, California 94105 U.S.A. Phone: 877-277-7585 Fax: 415-576-9217 Send questions and comments to the BioSpace News Beat Team. Editor & Publisher: Rosemary Do Editorial & Production Staff: Lana Ho, Maysa Darwish, Tammy Liu, Michelle Wong BioSpace.com - Life. Science. Community. • BioSpace is a registered trademark of BioSpace, Inc. • Please distribute this e-cast freely. • Credit any excerpts as follows: Copyright 2012 BioSpace http://www.biospace.com • While BioSpace and its agents used their best efforts in collecting and preparing the information published herein, we do not assume, and hereby disclaim, any liability for any loss or damage caused by errors or omissions, whether such errors or omissions resulted from negligence, accident or other causes. If someone forwarded this news to you and you'd like to receive your own copy FREE of charge, simply Subscribe here. Safely unsubscribe from Biospace.com e-mail at any time by managing your account here.